[Effect of medroxyprogesterone acetate on the cell kinetics in primary breast cancer].
Effect of medroxyprogesterone acetate (MPA) on the breast cancer cell kinetics was investigated by flow cytometry on paraffin-embedded tissues. Nuclear DNA contents were measured in 67 primary cases. MPA, 1,2000 mg/day, was administered orally for two weeks in 12 cases (MPA group) and the remaining cases (n-MPA group) served as the controls, until the day before operation. The DNA histograms were compared between both groups. The mean percentage of G0 + G1 phase was higher and that of S-phase and G2 + M phase, lower, in the MPA group than those in the n-MPA group. Especially in estrogen receptor positive and premenopausal cases, a significant difference was present between both groups. These results suggest that MPA could inhibit DNA synthesis with a delay of the cell cycle progression in human breast cancer.
Doihara
H
H
Dept. of Surgery, Shikoku Cancer Center Hospital, Matsuyama, Japan.
Takashima
S
S
Saeki
H
H
Takiyama
W
W
Kurita
A
A
Soga
H
H
Tanada
M
M
Yokoyama
N
N
Moriwaki
S
S
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002453:Cell Cycle / Q000187:drug effects; D004273:DNA, Neoplasm / Q000032:analysis; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008593:Menopause; D008875:Middle Aged; D010908:Pituitary Hormones, Anterior / Q000097:blood; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D010908:Pituitary Hormones, Anterior; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone